Compare ADPT & UNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | UNF |
|---|---|---|
| Founded | 2009 | 1936 |
| Country | United States | United States |
| Employees | 624 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.0B |
| IPO Year | 2019 | 1994 |
| Metric | ADPT | UNF |
|---|---|---|
| Price | $28.51 | $261.62 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 3 |
| Target Price | $17.78 | ★ $238.33 |
| AVG Volume (30 Days) | ★ 1.8M | 291.0K |
| Earning Date | 05-05-2026 | 04-01-2026 |
| Dividend Yield | N/A | ★ 0.57% |
| EPS Growth | ★ 63.89 | 2.70 |
| EPS | N/A | ★ 4.11 |
| Revenue | $276,976,000.00 | ★ $1,696,489,000.00 |
| Revenue This Year | $3.98 | $3.69 |
| Revenue Next Year | $22.72 | $3.53 |
| P/E Ratio | ★ N/A | $63.66 |
| Revenue Growth | ★ 54.77 | 6.63 |
| 52 Week Low | $12.00 | $147.66 |
| 52 Week High | $28.72 | $306.67 |
| Indicator | ADPT | UNF |
|---|---|---|
| Relative Strength Index (RSI) | 73.65 | 25.49 |
| Support Level | $23.73 | $258.79 |
| Resistance Level | N/A | $264.88 |
| Average True Range (ATR) | 1.06 | 7.08 |
| MACD | 0.37 | -1.47 |
| Stochastic Oscillator | 97.40 | 19.35 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
UniFirst Corp provides uniform and workwear programs, facility management, and safety supplies and services across North America. It designs, manufactures, rents, cleans, and sells uniforms and protective clothing, including flame-resistant and high-visibility garments. It also offers industrial wiping products, floor mats, cleaning supplies, first aid cabinets, and fire protection services such as inspection and maintenance. Serving various industries, the company provides customized uniforms and specialized cleaning for nuclear and cleanroom facilities. It operates through three segments: Uniform & Facility Service Solutions, First Aid & Safety Solutions, and Other, with the majority of revenue from Uniform & Facility Service Solutions.